Up­dat­ed: J&J builds out glob­al man­u­fac­tur­ing ca­pac­i­ty for CAR-T Carvyk­ti

John­son & John­son is ramp­ing up man­u­fac­tur­ing ca­pac­i­ty for the CAR-T ther­a­py it de­vel­oped with Leg­end Biotech, dri­ven by high de­mand for the Carvyk­ti, ex­ec­u­tives said Tues­day.

“We’ve been pro­gres­sive­ly adding more and more ca­pac­i­ty,” John Reed, J&J’s EVP of phar­ma­ceu­ti­cals and R&D, said dur­ing a third-quar­ter earn­ings call.

That in­cludes more ca­pac­i­ty at sites in New Jer­sey, Bel­gium and Switzer­land, plus ex­cess ca­pac­i­ty from No­var­tis. J&J and No­var­tis an­nounced plans ear­li­er this year to part­ner on Carvyk­ti man­u­fac­tur­ing. J&J al­so has “an­oth­er fac­to­ry in the Nether­lands to sup­port the lentivirus com­po­nent,” which is set to open in 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER